× ×ª×× × ×ª×¨×פ×
××רש×
| ××× ×× ×× × ×ספ××
|
|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4)
|
L01FE
EGFR (Epidermal Growth Factor Receptor) inhibitors
|
| ×ר××× ×¤×¢×× (ATC5)
|
Â
|
| צ×רת ×ת×
|
ת××-×ר××× - I.V
|
| צ×רת ××× ××
|
ת×××¡× ×××× ×¤××××, SOLUTION FOR INFUSION
××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר××
|
| ×ת××××
|
Erbitux® is indicated for the treatment of patients with epidermal growth factor receptor (EGFR) - expressing, RAS wild-type metastatic colorectal cancer⢠In combination with irinotecan-based chemotherapy⢠In first-line in combination with FOLFOX⢠as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecanErbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck (SCCHN)⢠in combination with radiation therapy for locally advanced disease⢠in combination with platinum-based chemotherapy for recurrent and/or metastatic disease⢠as a single agent after failure of platinum-based chemotherapy for recurrent and/or metastatic disease
|
| × ×ª×× × ×ס×
|
ת×ר×× ××××× ×ס×
- 20/09/2006
|
×××××ת ×ס×
- תר××¤× ×××××ת ×ר×ש×× ×¢'× ×¨××¤× ××××× ×× ××××× ××רת
|
×ת×××× ×ס×
| ×ת×××× |
ת×ר×× ××××× |
ת××× ×§××× × |
Class Effect |
××¦× ×××× |
×ס×ס ×××××ת
|
| ×ש×××× ×¢× ××××תרפ×× ×××פ×× ×סר×× ××¢× ×ס ×ר××¨×ª× ××§× ××פ×× ×¨×ש×× ×× ××§× ××פ×× ×תק×× (×©× × ×××××), ×¢××ר ××××× ×¢× ××××××× ××× ×××צ×× ×-KRAS. |
20/09/2006 |
|
|
|
|
| ×ש×××× ×¢× ××××תרפ×× ×× ×ת×ש×ר ×××× ×××פ×× ×סר×× ×ר××¨×ª× ×/×× ×××ר ×©× ×ר×ש ××צ×××ר ×ס×× ×ª××× ×§×©×§×©××× (SCCHN - Squamous cell carcinoma of the head and neck). |
20/09/2006 |
|
|
|
|
| ×ש×××× ×¢× ××§×¨× ×ת ×××פ×× ×סר×× ×¨×ש צ×××ר ×תק×× ×ק××× ×ס×× ×ª××× ×§×©×§×©××× (Squamous cell carcinoma of the head and neck - SCCHN). |
20/09/2006 |
|
|
|
|
|
ש×××ש ×ס×
-
|
×ס×רת ××××× ×ס×
- ×תר××¤× ×ª×× ×ª× ×××פ×× ××קר×× ××××:
- ×ש×××× ×¢× ××§×¨× ×ת ×××פ×× ×סר×× ×¨×ש צ×××ר ×תק×× ×ק××× ×ס×× ×ª××× ×§×©×§×©××× (Squamous cell carcinoma of the head and neck - SCCHN)
- ×ש×××× ×¢× ××××תרפ×× ×× ×ת×ש×ר ×××× ×××פ×× ×סר×× ×ר××¨×ª× ×/×× ×××ר ×©× ×ר×ש ××צ×××ר ×ס×× ×ª××× ×§×©×§×©××× (SCCHN - Squamous cell carcinoma of the head and neck)
- ×ש×××× ×¢× ××××תרפ×× ×××פ×× ×סר×× ××¢× ×ס ×ר××¨×ª× ××§× ××פ×× ×¨×ש×× ×× ××§× ××פ×× ×תק×× (×©× × ×××××), ×¢××ר ××××× ×¢× ××××××× ××× ×××צ×× ×-KRAS
- ק××× ××××× ××פ×× ×××ת ××תר×פ×ת Cetuximab ×× Panitumumab, ×× ×ק×× ××פ×× ×תר××¤× ×××רת, ××××× ××
- ×××פ×× ×ת×ש×ר ××× ×ª× ××××× ×©××¨× ×××¤× ×-Cetuximab ××××× ××, ×××¢× ××××× ×סר×× ××¢× ×ס ×× ×¨×§××× ×ר×רת×, ×××××¤× ×ש×××× ×©× Cetuximab ×¢× Encorafenib, ×שר ק××× ××פ×× ×§××× ××××ת×, ××××× ×××צ×× ×ס×× BRAF V600E
- ××ª× ×תר××¤× ×××¢×©× ××¤× ××¨×©× ×©× ××××× ×××× ×§××××××
|
|
| ×¢××× ×ר××¤× ××××ר×ת ××¢×××
|
Â
Â
|
| ××פ×ש ×××ר××
|
×××ר×× ×-PubMed
|
| ××××¢ ×רשת
|
RxList WebMD Drugs.com
|
| ×©× ×צר×
|
MERCK KGaA, GERMANY
|
| ×©× ××¢× ×ר×ש××
|
MERCK SERONO LTD
|
| ר×ש×××
|
ת×ר×× ××ש×: 04/2008. ר×ש××× ×ת×ר××: 07/2014
|
| ת×ר×× ×¢×××× ××ר××
|
05/03/2025
|
ת××× ×ª ×ר×××
ת×ר×× ×¢××××: 05/03/2025
Merck
×ר××××קס - Erbitux
true
×××ר××
×צפ××× ×××××¢ ××ר×× ×ר×פ××× ×ש
××××× ×¡ ××ש××× ×. ×× ××× × ×¨×©×× ××× ×¡ ×
×רש×× ×ר×פ××× ××× ×©× ×קצ××¢×ת רפ×××××.
השינוי האחרון נעשה בֹ־5 במרץ 2025 ב־13:14
